Posted by Squiggles on May 8, 2006, at 8:21:32
In reply to Re: Statistical question on SSRIs, posted by SLS on May 8, 2006, at 7:45:41
Thank you for your reply.
> Reboxetine was denied approval by the FDA several years ago because the clinical investigations performed in the US were failed studies. Neither reboxetine nor fluoxetine demonstrated superiority over placebo.
But fluoxetine is a big seller, no? The
studies at PubMed compare fluoxetine to
Reboxetine, and find the majority of Reboxetine
more potent, less annoying in side effects,
and at least as effective as Prozac (which i
think is fluoxetine -- hope i didn't get that
wrong).
>
> My impression over these last five years is that reboxetine is not as effective as desipramine as a NARI.Desipramine - a tricyclic?. Reboxetine is said
to be unique as an NARI - not like the other
NARIs.A few people have responded favorably to it, but it seems that many more have not.
You probably have access to data on this.
>
> My personal experience with reboxetine was that it made my depression significantly worse and produced anxiety.Hmm, i appreciate the feedback.
>
> I did not like atomoxetine. It produced fatigue and did not help much with depression.
>
> I am very treatment-resistant, so my reactions to these drugs may not be typical.That's important to me - we are dealing with
a treatment-resistant case and a sledgehammer
seems necessary. I have had my doubt about
classes outside the tricyclics and anti-psychotics
for this case. Maybe just an opinion, but
the SSRIs and NARIs seem a class of perkier,
but not as sedating drugs.It's possible that what we have with the
HEALY case is a fight which could be terribly
immoral if it affected lives, but if the two
drugs are more or less equivalent in sucicidality
rates, and efficacy rates, the fight only affects
reputation and personal antagonism. I love
self-interest :-)
>
>
Squiggles> - Scott
poster:Squiggles
thread:640557
URL: http://www.dr-bob.org/babble/20060504/msgs/641261.html